Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. … Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main

    Categories: Growth Hormone Receptor Antagonist, Growth Hormone Receptor AntagonistsProducts: SOMAVERT 10 MG ENJEKSIYONLUK COZELTI ICIN TOZ ICEREN FLAKON VE COZUCU, 30 ADET, SOMAVERT 15 MG ENJEKSIYONLUK COZELTI ICIN TOZ ICEREN FLAKON VE COZUCU, 30 ADET
  2. Drug

    Nortriptyline

    go.drugbank.com/drugs/DB00540
    ApprovedInvestigational

    Nortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA). … [L11878] It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.[L11881]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor Antagonists
  3. Drug

    Dapsone

    go.drugbank.com/drugs/DB00250
    ApprovedInvestigational

    It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) … Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms.

  4. Target

    Inositol 1,4,5-trisphosphate-gated calcium channel ITPR2

    go.drugbank.com/bio_entities/BE0009594
    TargetHumans

    Inositol 1,4,5-trisphosphate-gated calcium channel that upon inositol 1,4,5-trisphosphate binding transports calcium from the endoplasmic reticulum lumen to cytoplasm. Exists in two states; a long-lived closed state where the channel is ...

    Synonyms: IP3 receptor isoform 2, Type 2 InsP3 receptor
  5. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    It is used to treat metastatic castration-resistant prostate cancer, hormone-sensitive high-risk metastatic prostate cancer. … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.

  6. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. … Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis.

    Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists
  7. Drug

    Spectinomycin

    go.drugbank.com/drugs/DB00919
    ApprovedVet approvedWithdrawn

    It is active against gram-negative bacteria and used for the treatment of gonorrhea.

  8. Drug

    Loxapine

    go.drugbank.com/drugs/DB00408
    ApprovedInvestigational

    An antipsychotic agent used in schizophrenia. [PubChem]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor Antagonists
  9. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    [L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. … [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

    Products: PANZYTRAT OK MA RE MICROTA, CREON® CAPSULAS DE LIBERACION RETARADADA 10.000
  10. Drug

    Propranolol

    go.drugbank.com/drugs/DB00571
    ApprovedInvestigational

    Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. … [L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor Antagonists